Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
MARLBOROUGH, Mass. & SAN DIEGO--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) and Afraxis, Inc. today announced that they have signed a partnership agreement to utilize the unique Enhanced Spine Platform (ESP) developed by Afraxis, Inc. to accelerate Sunovion’s preclinical central nervous system (CNS) drug discovery process. The use of this proprietary platform will allow Sunovion to identify novel CNS compounds that are potentially superior to existing treatments. While the full financial terms have not been disclosed, Afraxis will be eligible for certain milestone payments for each compound through phase 2 clinical trial initiation.
Help employers find you! Check out all the jobs and post your resume.
